Serološki odgovor goveda na cijepljenje polivalentnim cjepivom protiv slinavke i šapa, bjesnoće, hemoragijske septikemije i šuštavca.

Five groups of ten animals were vaccinated with a combined vaccine containing foot and mouth disease (FMD), rabies, Pasteurella multocida and Clostridium chauvoei antigens and individual component vaccines containing FMD, rabies, Pasteurella multocida and Clostridium chauvoei antigens, respectively. Serological response of the calves was assayed on days 21 and 90 post vaccination. There was no significant variation in the serological response elicited by individual component vaccines and combined vaccine containing all four antigens.Pet skupina po deset životinja cijepljeno je različitim kombinacijama vakcina. Prva je skupina cijepljena polivalentnim cjepivom koje je sadržavalo antigene virusa slinavke i šapa, virusa bjesnoće te bakterija Pasteurella multocida i Clostridium chauvoei. Ostale su skupine cijepljene pojedinačnim antigenima, pa je tako druga skupina cijepljena antigenima virusa slinavke i šapa, treća antigenima virusa bjesnoće, četvrta antigenima bakterije Pasteurella multocida, a peta antigenima bakterije Clostridium chauvoei. Serološki odgovor svih životinja provjeren je 21. i 90. dana nakon cijepljenja. Na osnovi serološkoga odgovora nisu utvrđene značajne razlike među različitim načinima cijepljenja

Generation and Characterization of an scFv Directed against Site II of Rabies Glycoprotein

Recombinant antibody phage display technology is a vital tool that facilitates identification of specific binding molecules to a target enabling the rapid generation and selection of high affinity, fully human, or mouse antibody product candidates essentially directed towards disease target appropriate for antibody therapy. In this study, a recombinant single-chain Fv antibody fragment (scFv) A11 was isolated from immune spleen cells obtained from mice immunized with inactivated rabies virus (Pasteur strain) using standard methodology and was characterized for its specificity towards the rabies virus glycoprotein. Epitope mapping using peptide libraries and truncated glycoprotein polypeptides suggested that A11 bound to the antigenic site II of rabies glycoprotein against which a majority of rabies virus neutralizing antibodies are directed. The use of the above technology could, therefore, allow development of scFvs with different specificities against the rabies glycoprotein as an alternative to the more cumbersome protocols used for the development of monoclonal antibodies

A Brucella abortus S19 Glyco-conjugate Vaccine Consisting of Lipopolysaccharide and outer Membrane Protein Protects Mice against Challenge with Brucella abortus

A glyco-conjugate vaccine using the lipopolysaccharide (LPS) and the outer membrane protein (OMP) of Brucella abortus S19 strain was prepared. The vaccine was administered in mice subcutaneously (25 µg LPS per dose). Separate groups of mice were also vaccinated with LPS, OMP or live, attenuated S19 vaccine. Mice were challenged 30 days post vaccination with B. abortus 544 strain. The LPS, OMP and LPS-OMP glyco-conjugate vaccinated mice were protected against the challenge. The percentage of animals protected with the sub-unit vaccines and the glyco-conjugate vaccine were comparable with the live, attenuated vaccine. The glyco-conjugate vaccine was able to induce strong immune response against both the components. The prominent isotypes were IgG1, IgG2a and IgG3. In addition, the glyco-conjugate vaccine was able to induce a cell mediated immune response as indicated by the expression of IFN γ by splenocytes. The study indicated that the glyco-conjugate vaccine may be a useful candidate for prophylactic use

Serološki odgovor goveda na cijepljenje polivalentnim cjepivom protiv slinavke i šapa, bjesnoće, hemoragijske septikemije i šuštavca.

Five groups of ten animals were vaccinated with a combined vaccine containing foot and mouth disease (FMD), rabies, Pasteurella multocida and Clostridium chauvoei antigens and individual component vaccines containing FMD, rabies, Pasteurella multocida and Clostridium chauvoei antigens, respectively. Serological response of the calves was assayed on days 21 and 90 post vaccination. There was no significant variation in the serological response elicited by individual component vaccines and combined vaccine containing all four antigens.Pet skupina po deset životinja cijepljeno je različitim kombinacijama vakcina. Prva je skupina cijepljena polivalentnim cjepivom koje je sadržavalo antigene virusa slinavke i šapa, virusa bjesnoće te bakterija Pasteurella multocida i Clostridium chauvoei. Ostale su skupine cijepljene pojedinačnim antigenima, pa je tako druga skupina cijepljena antigenima virusa slinavke i šapa, treća antigenima virusa bjesnoće, četvrta antigenima bakterije Pasteurella multocida, a peta antigenima bakterije Clostridium chauvoei. Serološki odgovor svih životinja provjeren je 21. i 90. dana nakon cijepljenja. Na osnovi serološkoga odgovora nisu utvrđene značajne razlike među različitim načinima cijepljenja

A noval vaccine formulation consisting of DNA vaccine inactivated virus

Disclosed herein is a novel vaccine formulation for prophylactic or therapeutic immunization of vertebrates against infections caused by vertebrate viruses. The said vaccine contains a min. of two components, one of which is a deoxyribonucleotide (DNA) vaccine comprising of a DNA mol. that encodes a polypeptide of the virus and the other component consisting of inactivated form of the virus. This invention can also be used to develop low cost inactivated virus-based vaccines that contain much lower amt. of the said virus than that present in similar vaccines known in the prior art. The examples focus on the methods of producing a novel vaccine compn. against the rabies virus

Molecular Characterization of Foot-and-Mouth Disease Virus Type C of Indian Origin

Comparison of nucleotide sequences of the partial 1D region of foot-and-mouth disease type C viruses of Indian origin with those of European, South American, and Southeast Asian viruses revealed that the Indian viruses form a distinct genotype. The vaccine strain C IND/51/79 belongs to this genotype and may be a prototype strain of this genotype

Assessment of immunoprophylactic efficacy of recombinant mid gut antigen (Bm95) of Rhiphicephalus microplus in Bos indicus

Use of recombinant Bm95 isolated from an Argentinean strain of Rhiphicephalus microplus A as a vaccine candidate to control the tick infestation in India was investigated. Recombinant Bm95 expressed in yeast, Pichia pastoris. Purified protein blended into a vaccine using aluminium hydroxide as an adjuvant. An adverse effect on the reproduction of ticks was observed in vaccinated animals indicating reduced the environmental contamination and source of infestation indicating its use of Bm95 in the immunological control of ticks in India

Recombinant mid gut antigen (Bm95) as a vaccine against Indian Rhiphicephalus haemaphysaloides in Bos indicus cattle

In the present study, we report for the first time the efficacy of recombinant Bm95 mid gut antigen isolated from an Argentinean strain of Rhipicephalus microplus strain A in controlling the tick infestations in India. The synthetic gene for Bm95 optimized for expression in yeast was obtained and used to generate yeast transformants expressing Bm95 which was purified to apparent homogeneity. Liquid chromatography-mass spectrometry analysis of the purified protein confirmed its identity as Bm95. Vaccine was prepared by blending various concentrations of purified Bm95 with aluminium hydroxide as an adjuvant. lmmunogenicity studies of the vaccine in rabbits and cattle indicated that the vaccine was highly immunogenic. The efficacy studies of the vaccine was done in cattle. Naive Bos indicus cattle were vaccinated with the recombinant vaccine and were challenged with the larval, nymphal and adult forms of Rhiphicephalus haemaphysaloides. The vaccine protected the animals from larval, nymph and adult tick challenges with an efficacy of 98.7%, 84.6% and 78.9% respectively. The results obtained from the above studies clearly demonstrated the advantage and possibilities of the use of Bm95 in controlling R. haemaphysaloides infestations in the field. (C) 2010 Elsevier Ltd. All rights reserved